Antibody Ingredients TRIZ Cases

Grafting murine complementarity-determining regions onto human antibody frameworks reduces immunogenicity while maintaining binding specificity.

Cytoreductive preliminary actions reduce circulating tumor cell burdens, enabling safe dose escalation of anti-CD47 agents to minimize toxicity.

Merging PD-L1 blockade with CD137 agonism in one molecule simplifies dosing while amplifying immune response against tumors.

Human monoclonal antibodies target MASP-2 to inhibit lectin pathway initiation, preventing tissue damage while preserving classical pathway function.

Anti-KIR3DL2 agents deplete tumor cells while preserving healthy immune function, resolving the contradiction between efficacy and cytopenia.

Merging CD20 and CD28 targeting into one molecule redirects T cells to destroy malignant B cells while minimizing peripheral toxicity.

A humanized single-chain antibody binds the GPIIIa49-66 epitope on platelets to induce oxidative fragmentation.

Anti-Galectin-9 antibodies disrupt Galectin-9 interactions to restore anti-tumor immunity and reduce tumor burden in solid tumors.

Bispecific antibodies bind LILRB1 and LILRB2, blocking HLA-G interactions to reverse immune suppression in cancer treatment.

Phage display and genetic engineering produce high-purity antihuman PCSK9 antibodies that inhibit colorectal cancer while reducing chemotherapy toxicity.

Anti-CD69 antibody blocks neutrophil infiltration and aggregation in lungs, reducing mortality rates from fulminant acute pneumonia.

Administering PD-1 and PD-L1 antagonists within four days of radiation therapy overcomes immune escape to improve local tumor control.

Humanized antibody HKLD reduces immunogenicity while maintaining high binding affinity and macrophage phagocytosis.

Modified amino acid sequences in variable domains reduce aggregation propensity to improve antibody yield without compromising therapeutic efficacy.

Humanized antibodies bind OX40 receptors to activate immune responses while reducing immunogenicity from anti-mouse reactions.

Combining mini-intronic plasmid DNA vaccines with LAG-3 blockade overcomes immune checkpoint inhibition to enhance tumor treatment efficacy.

Fc-modified anti-CD154 antibodies minimize thromboembolic events while maintaining efficacy against CD154:CD40 interactions.

Platelet-conjugated anti-PDL1 targets surgical sites to reduce systemic side effects and prevent cancer recurrence.

Segmented bispecific antibodies overcome biodistribution challenges by enabling targeted T cell activation against tumors.

Novel anti-CD38 binding domains with specific amino acid sequences overcome limitations of existing antibodies to improve treatment effectiveness.

A monoclonal antibody binds to fibroblast growth factor receptor 1 domains II and IIIc to block the FGF/FGFR1 signaling pathway.

Adjusting Fab glycosylation controls circulation half-life while preserving Fc-mediated ADCC activity and antigen binding.

Combining this peptide complex with immuno-oncology agents increases tumor-infiltrating immune cells to improve anti-tumor activity.

Targeting KLRG1 with binding agents limits type-2 cytokine production and alleviates eosinophilia in allergic disorders.

Antibodies targeting the CD33D2 isoform lacking the IgV domain restore therapeutic efficacy for patients unresponsive to wild-type treatments.

Multispecific antibodies bind CEACAM1, CEACAM5, and CEACAM6 to block immune suppression.

Targeted amino acid substitutions resolve the trade-off between humanization and binding affinity in anti-CD47 antibodies.

Inhibitors targeting Type 1 interferon signaling prevent genomic lesion-triggered apoptosis, addressing ineffective conventional neurodegeneration treatments.

Targeting TIRC7 reduces harmful cytokine bursts while preserving viral defense capabilities.

Optimized anti-CD38 antibodies maintain cross-reactivity with cynomolgus monkey CD38 while minimizing non-specific immune responses through Fc region mutations.

Humanized anti-PD-1 antibodies resolve the contradiction between antitumor activity and immunogenicity by maintaining efficacy while reducing immune response.

Anti-CCR8 antibodies deplete immunosuppressive Tregs via ADCC, resolving checkpoint inhibitor limitations in breast and prostate cancer.

Targeting surface-expressed CAPRIN-1 with specific antibodies achieves selective cancer treatment while sparing normal cells.

Humanized monoclonal antibodies targeting CD99 reduce host immune responses while maintaining therapeutic efficacy against Ewing sarcoma and leukemia.

A bispecific antibody binds cancer cells via CSPG5 and T cells via CD3 to trigger targeted immune destruction.

Humanized monoclonal antibodies bind the metalloprotease domain of ADAMTS13 to block VWF cleavage.

Fully human antibodies with engineered complementarity-determining regions block TIGIT ligand interactions to enhance anti-tumor immune responses.

Engineered cysteine residues in antibody variable regions enable site-specific drug conjugation without reduction treatment.

Genotyping IL6R variants enables anti-IL6R ligand selection that reduces side effects while improving treatment outcomes.

Combining anti-B7-H4 antibodies with PD-1 antagonists overcomes insufficient single-agent efficacy in solid tumors.

Anti-OX40 monoclonal antibodies with specific variable region sequences prolong T cell survival and expand memory populations.

Targeting SFRP2, JAK3, and FAP markers overcomes limited understanding of specific genes expressed in tumor blood vessels.

Optimized antibody variable regions enhance binding affinity and persistence in the bloodstream while reducing immunogenicity through humanization.

Antibody targeting partial CAPRIN-1 polypeptide sequence resolves contradiction between antitumor activity and adverse reactions in normal cells.

Administering an ST2 antagonist targets the IL-33 pathway to reduce exacerbation frequency and improve lung function in chronic obstructive pulmonary disease.

Single domain mesothelin binding proteins direct T cells to kill tumor cells, improving therapeutic efficacy against aggressive cancers.